Aligos settles Janssen lawsuit; dismisses counterclaims, releases all parties

Aligos Therapeutics, Inc.

Settlement agreement entered Oct 16, 2023 with Janssen Biotech resolving breach of contract and tortious interference claims.
Janssen dismisses action and releases Aligos, CEO Lawrence Blatt, and President Leonid Beigelman from all claims.
Aligos dismisses counterclaims for unfair competition and promissory fraud and releases Janssen.
No admission of liability or financial terms of settlement disclosed in the filing.
Litigation involved intellectual property ownership and claims against top executives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.